Akèy › Kansè Poumon ki pa ti selil › Ohio › Akron
Etid klinik pou Kansè Poumon ki pa ti selil nan Akron, OH
22 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Akron (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Cleveland Clinic Akron General, Akron
- Aultman Health Foundation, Canton · 21 mi lwen
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Aultman Health Foundation, Canton · 21 mi lwen
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Ap rekriteFaz 3
- Akron General Medical Center, Akron
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Aultman North, North Canton · 15 mi lwen
- Aultman Massillon, Massillon · 20 mi lwen
- Aultman Orrville Hospital, Orrville · 21 mi lwen
- ak 2 plis
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Canton · 21 mi lwen
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Aultman Hospital, Canton · 21 mi lwen
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Gabrail Cancer Center, Canton · 21 mi lwen
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Gabrail Cancer Center Research, Canton · 21 mi lwen
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Ap rekriteFaz 2
- Gabrail Cancer Center, Canton · 21 mi lwen
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Tricounty Hematology and Oncology - Massillon, Massillon · 20 mi lwen
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Ap rekriteFaz 1/2
- Gabrail Cancer Center Research, Canton · 21 mi lwen
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Gabrail Cancer Center, Canton · 21 mi lwen
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Ap rekriteFaz 2
- Gabrail Cancer and Research Center, Canton · 21 mi lwen
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Cleveland Clinic Mercy Hospital, Canton · 21 mi lwen
- Aultman Health Foundation, Canton · 21 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Aultman Health Foundation, Canton · 21 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Aultman Health Foundation, Canton · 21 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Aultman Health Foundation, Canton · 21 mi lwen
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- Aultman Hospital, Canton · 21 mi lwen
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Ap rekriteFaz 1
- Gabrail Cancer & Research Center, Canton · 21 mi lwen
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 138, Canton · 21 mi lwen
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Ap rekriteFaz 1/2
- Gabrail Cancer Center Research, Canton · 21 mi lwen
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Ap rekriteFaz 1/2
- Gabrail Cancer Research Center, Canton · 21 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Akron
- Kansè poumon16 etid
- Kansè (tout kalite)13 etid
- Kansè nan tete13 etid
- Kansè pwostat9 etid
- Leksemi mieloïd egi8 etid
- Melanom8 etid
- Kansè poumon selil ti8 etid
- Kansè Metastatik8 etid
- Kansè kolorektal8 etid
- Maladi fwa steatotik7 etid
- Kansè Endomèt6 etid
- Kansè ovè6 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.